EUVIMEDEUVIMED entdecken
Editorial

Semaglutide for Metabolic Dysfunction–Associated Steatohepatitis

Tracey G Simon iD

New England Journal of Medicine · 05.06.2025 · 392 (21) · 2160-2161

DOI: 10.1056/nejme2504717 ↗

Kurz gefasst

Editorial in der Zeitschrift New England Journal of Medicine, erschienen am 05.06.2025. Verfasst von Tracey G Simon. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction–associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease that affects more than 30% of adults worldwide. 1 Up to one third of patients with MASLD have progressive steatohepatitis (MASH) and fibrosis, which can lead to cirrhosis and death. 2 MASH is also associated with an excess risk of cardiovascular disease, a finding that underscores the importance of simultaneously addressing cardiometabolic risk factors in the treatment of this disease. 2 Currently, the only medication conditionally approved for the treatment of MASH with fibrosis is resmetirom — a liver-directed thyroid hormone receptor beta-selective agonist. Thus, additional therapies are still . . .

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston.
  • Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston.
  • Harvard Medical School, Boston.
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston.

ORCID-Profile: Tracey G Simon

Zitieren

APA

Simon, T. G. (2025). Semaglutide for Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine, 392(21), 2160-2161. https://doi.org/10.1056/nejme2504717

Vancouver

Simon TG. Semaglutide for Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine. 2025;392(21):2160-2161. doi:10.1056/nejme2504717

BibTeX
@article{Simon2025,
  author = {Simon, Tracey G},
  title = {Semaglutide for Metabolic Dysfunction–Associated Steatohepatitis},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {21},
  pages = {2160--2161},
  doi = {10.1056/nejme2504717}
}
Kostenlos starten →